VEGFA and non-small cell lung carcinoma: Some researchers have noted that DEX could promote tumor growth via activation of α2‐adrenoreceptors (expressed on cancer cells or host stromal cells) or imidazoline receptor, which increases the formation of hypoxia-inducible factor and vascular endothelial growth factor involved in the proliferation and growth of non-small cell lung cancer cells40–42.